GNI Group Ltd. (DE:3G6)
FRANKFURT:3G6
3G6 Stock Chart & Stats
€16.40
€0.40(2.20%)
At close: 4:00 PM EST
€16.40
€0.40(2.20%)
Day’s Range― - ―
52-Week Range€8.80 - €26.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€952.57M
Enterprise Value€159.39B
Total Cash (Recent Filing)€21.10B
Total Debt (Recent Filing)€5.37B
Price to Earnings (P/E)―
Beta1.10
Next Earnings
May 15, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding55,698,696
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.52
Price to Sales (P/S)4.71
P/FCF Ratio-46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€20.66Price Target Upside25.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.29
Revenue Forecast (FY)€180.55M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low debt and materially higher equity provide lasting financial flexibility. This reduces refinancing and interest-rate risk, supports funding of R&D or clinical programs without immediate external capital, and cushions the business through cyclical biotech funding windows over the next 2–6 months.
High Gross MarginsSustained high gross margins indicate strong product economics and pricing power for core therapies. This structural margin advantage can absorb higher operating expenses, support funding of development pipelines, and improve long-term unit profitability once operating leverage returns.
Diversified Revenue & PipelineMultiple revenue streams—product sales, licensing, R&D partnerships, and royalties—reduce single-product dependency. A robust pipeline and licensing model create recurring milestone/royalty prospects and strategic partnership optionality, structurally lowering commercialization risk over coming months.
Bears Say
Sustained Negative Cash FlowTwo consecutive years of negative operating and free cash flow signal the business is not self-funding. Persistent cash burn increases reliance on external financing, which can dilute equity or increase leverage and constrain R&D or commercialization timing over the medium term.
Profitability DeteriorationA sharp swing to meaningful net losses reduces earnings quality and limits internal reinvestment capacity. If elevated operating costs or non-recurring charges persist, restoring sustainable profitability will be required to support long-term growth and investor confidence.
Volatile Revenue TrajectoryInconsistent top-line performance complicates forecasting and resource allocation for clinical programs and commercialization. Revenue volatility raises execution risk for multi-stage projects and can weaken negotiating leverage with partners or payors over the next several quarters.
GNI Group News
3G6 FAQ
What was GNI Group Ltd.’s price range in the past 12 months?
GNI Group Ltd. lowest stock price was €8.80 and its highest was €26.00 in the past 12 months.
What is GNI Group Ltd.’s market cap?
GNI Group Ltd.’s market cap is €952.57M.
When is GNI Group Ltd.’s upcoming earnings report date?
GNI Group Ltd.’s upcoming earnings report date is May 15, 2026 which is in 39 days.
How were GNI Group Ltd.’s earnings last quarter?
GNI Group Ltd. released its earnings results on Feb 13, 2026. The company reported -€0.405 earnings per share for the quarter, missing the consensus estimate of €1.222 by -€1.626.
Is GNI Group Ltd. overvalued?
According to Wall Street analysts GNI Group Ltd.’s price is currently Undervalued.
Does GNI Group Ltd. pay dividends?
GNI Group Ltd. does not currently pay dividends.
What is GNI Group Ltd.’s EPS estimate?
GNI Group Ltd.’s EPS estimate is -0.01.
How many shares outstanding does GNI Group Ltd. have?
GNI Group Ltd. has 55,698,696 shares outstanding.
What happened to GNI Group Ltd.’s price movement after its last earnings report?
GNI Group Ltd. reported an EPS of -€0.405 in its last earnings report, missing expectations of €1.222. Following the earnings report the stock price went down -3.676%.
Which hedge fund is a major shareholder of GNI Group Ltd.?
Currently, no hedge funds are holding shares in DE:3G6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GNI Group Ltd.
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
3G6 Stock 12 Month Forecast
Average Price Target
€20.66
▲(25.98% Upside)
Technical Analysis
Peptidream
―
SanBio Co
―
Sosei Group
―
Takara Bio Inc.
―
Japan Tissue Engineering Co., Ltd.
―
Options Prices
Currently, No data available
---